Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
Filing tables
Filing exhibits
- 10-K Annual report
- 4.7 Supplemental Indenture 5.75% 2022 Notes
- 4.9 Supplemental Indenture 7.25% 2022 Notes
- 4.12 Supplemental Indenture 2023 Notes
- 4.15 Supplemental Indenture 2025 Notes
- 10.28 Novartis License Agreement
- 10.32 Final Indemnification Agreement
- 10.33 Executive Employment Agreement
- 10.18.1 Biospecifics Technologies Amendment to 2ND Development and License Agreement
- 21.1 Subsidiaries
- 23.1 Consent of PWC LLP
- 23.2 Consent of Deloitte and Touche LLP
- 24.1 Power of Attorney
- 31.1 CEO Section 302 Certification
- 31.2 CFO Section 302 Certification
- 32.1 CEO Section 906 Certification
- 32.2 CFO Section 906 Certification
- Download Excel data file
- View Excel data file
Related press release
ENDPQ similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S‑8 (No. 333-194253, No. 333-204958) and Form S-3 (No. 333-204657) of Endo International plc of our report dated February 29, 2016 relating to the financial statements, financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10‑K.
/s/ PricewaterhouseCoopers LLP
Philadelphia, Pennsylvania
February 29, 2016